TAL1/LMO1 deregulation is more frequent in -lineage T-ALL, when it is predominantly due to SIL-TAL1 rearrangements in children but to currently unknown mechanisms in adolescents and adults. LMO2 was more frequently co-expressed with LYL1, predominantly in IM0/ / adult cases, than with TAL1. These age related changes in phenotype and oncogenic pathways probably reflect progressive changes in the thymic population at risk of malignant transformation.
Introduction
Human T lymphocytes are derived from pluripotent hemopoietic progenitors which migrate throughout life from the bone marrow to the thymus, where the majority of T cell development takes place. Progressive thymic atrophy during the first 2-3 decades of life leads to a reduction of thymic mass and, to a lesser extent, function 1, 2 The earliest thymic progenitor corresponds to a minor (less than 1% of thymocytes) sCD3 negative, CD4/CD8 double negative (DN) population which does not alter with age. [3] [4] [5] [6] In the neonatal murine thymus, the majority of lymphocytes belong to the -lineage: successful TCR rearrangement in a DN precursor in the presence of pT allows expression of the pre-TCR in association with CD3, progression to the CD4/8 double positive (DP) stage and massive thymocyte expansion, a process known as -selection 7 ; this population diminishes markedly with age, with a consequent increase in the proportion of DN cells.
T-ALLs corresponds to a heterogeneous group of acute leukemias arrested at various stages of lymphoid development. They account for 10-15% of pediatric and 25% of adult ALLs, with a relatively constant incidence up to the third decade. [8] [9] [10] Recognized T-ALL oncogenic pathways include transcriptional deregulation by juxtapositioning to one of the TCR loci, resulting in transcriptional deregulation of genes such as HOX11/TLX1, LMO2, LMO1, LYL1 and TAL1/SCL, each of which is present in less than 10% of cases. [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] More common genetic defects in T-ALL are sub-microscopic deletions of p16/INK4 in 40-80% 23, 24 or SIL-TAL1, in 10-25%. [25] [26] [27] Although the latter leads to a fusion transcript, there is no SIL-TAL1 chimeric protein, only deregulated TAL1 expression. 28 Cryptic translocations are also recognized, with the commonest being the t(5;14)(q35;q32), leading to overexpression of HOX11L2/TLX3, an orphan homeobox factor very similar to HOX11, in 25-30% of pediatric and 13% of adult T-ALLs. 22, [29] [30] [31] HOX11 deregulation in the t(10;14)(q24;q11) or t(7;10)(q35;q24) has been described in 4-10% of pediatric T-ALLs and up to 14% of adults, with a predominantly cortical phenotype and a favorable outcome. 12, 13, [32] [33] [34] [35] Although most HOX11 and HOX11L2+ T-ALLs express CD1a, the immunophenotype of the latter is heterogeneous and their precise stage of maturation arrest within early cortical thymocytes is not known. 22, 30, 36 T-ALLs are usually classified immunophenotypically on the basis of CD1a expression. 37 We have recently described a TCR based classification of T-ALLs which demonstrates that T-ALLs largely reproduce normal thymic development and allows separation of cases into -lineage, TCR expressing and immature/uncommitted (IM), TCR and cytoplasmic We then undertook to determine whether T-ALL oncogenic pathways are associated with specific subsets, intially demonstrating that PICALM-MLLT10/AF10 (referred to as CALM-AF10 here) is restricted to T-ALLs of the TCR lineage. 39 In the present study we have analysed the effect of age and thymic involution on the incidence and TCR based stage of We show that genetic subtype correlates closely with stage of maturation arrest, regardless of age, whereas the incidence of the different subtypes differ markedly, in keeping with agerelated changes in the thymocytes at risk of oncogenic transformation and/or variable latency.
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Material and Methods
Diagnostic peripheral blood or bone marrow samples from 173 T-ALLs, defined by expression of c/sCD3 and surface CD7 and negativity of CD19, were analyzed. Approval was obtained from the participating institutional review boards for these studies. Informed consent was provided according to the Declaration of Helsinki. The majority had greater than 90% blasts. 165 unselected patients, for which availability of material was the only potential bias, came from 25 clinical centers. The majority of adults were treated on the LALA94 multicenter protocol (coordinator Denis Fière) and the majority of children on the Immunophenotyping was performed in the diagnostic center on fresh material and completed at Necker from cryopreserved material, as previously described. 38 Samples with greater than 20% labeled cells after correction for the proportion of blasts and normal T lymphocytes were considered positive. DNA and RNA were extracted from fresh or cryopreserved cells. 45 TCR loci were analysed as previously described. 38, 46 cDNA synthesis was performed at Necker 38 , and RNA quality assessed and normalized by quantification of ABL on an ABI PRISM 7700 (Perkin-Elmer Applied Biosystems, Branchburg, New Jersey USA), using EAC guidelines. 47 Samples with cycle threshold (Ct) above 32 (threshold 0.1) were excluded. Amplification efficiency was assessed by the slope obtained from logarithmic dilutions of the HPB-ALL cell line (pT , RAG-1) 38 Transcript quantification was perfomed after normalization by the ABL housekeeping gene from the standard curves using the delta of delta CT method. 47 Primers and RQ-PCR probes are detailed in Table 1 .
Results
Adult T-ALLs are arrested at an earlier stage than pediatric cases T-ALLs from 165 unselected adults (n=80; >20 years), adolescents (n=45; 11-20 years) and children (n=40; <10 years) were divided into 2 major categories: mature TCR expressing, and TCR negative T-ALLs. The latter were divided into precursors (preand IM ) and immature (IM0/ / ) T-ALLs ( The incidence of HOX11, HOX11L2, SIL-TAL1 and CALM-AF10 deregulation is age dependent.
Normal PBMC, bone marrow and thymic controls showed absent or low level expression of both HOX11 and HOX11L2 (less than 100 copies), as did AMLs ( Sequence expression confirmed that these corresponded to true HOX11 transcripts (data not shown) but 0/5 analyzed showed 10q24 abnormalities, they have been classified as HOX11
negative. No sample showed both HOX11 and HOX11L2 positivity.
The incidence of HOX11L2 and SIL-TAL1 decreased with age whereas that of HOX11 increased ( Table 2) . IM CALM-AF10+ cases were exclusively adolescents and young adults (median age 25.5 years) whereas the rare pediatric CALM-AF10 cases expressed TCR 39 .
Amongst the 43 adults aged over 30 years the incidence of HOX11L2, SIL-TAL1 and CALM-AF10 were all 5%, whereas HOX11 was found in 28%.
HOX11 and SIL-TAL1 deregulation are virtually restricted to -lineage T-ALLs.
SIL-TAL1 and HOX11 deregulation was virtually absent from IM0/ / T-ALLs (Table 2) .
SIL-TAL1 was more common in TCR expressing (36%; 10/28) than precursor TALLs (14%; 10/70, p=0,02), irrespective of age group (Table 2) . In keeping with a late cortical stage of -lineage arrest, SIL-TAL1+ cases showed relatively low levels of RAG-1
For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From expression, particularly in TCR + cases (Fig. 2) . Despite the fact that enforced TAL1/SCL expression inhibits pT expression 44 , pT levels in SIL-TAL1 T-ALLs were similar to other -lineage cases (Table 3 and Fig. 2 ). TAL1 inhibits the CD4 proximal enhancer by titrating E2A/HEB 43 . SIL-TAL1 clearly does not prevent expression of CD4 on CD4/8 DP cells but CD4 SP SIL-TAL1+ T-ALLs were not seen and CD8 SP were relatively frequent, suggesting that TAL1 prevents the DP to CD4 SP transition rather than the DN to CD4
immature single positive (ISP)/DP transition.
HOX11 T-ALLs were virtually all arrested at the IM or prestage, with a strikingly uniform immunophenotype: CD1a+, CD10+, CD4/8 DP (or rarely CD4 SP) with high levels of pT and RAG-1 and frequent CD10 positivity but CD34, CD13 and CD33 negativity.
HOX11 and SIL-TAL1 are therefore virtually restricted to the -lineage, with an earlier stage of maturation arrest in HOX11 cases compared to SIL-TAL1 T-ALLs (Fig. 3 ).
HOX11L2 deregulation is associated with a maturation arrest intermediate between the and lineages.
HOX11L2+ expression was most common in IM (10/17; 59%), pre-(8/47; 17%) and TCR (7/33; 21%) T-ALLs ( In order to further analyze HOX11L2+ T-ALLs, we included 8 additional TCR T-ALLs (Table 3) . Within TCR T-ALLs, HOX11L2 expressing cases were more likely to express CD34, CD4/8 DP, CD1a, CD10, and strikingly, RAG-1, pT and cTCR , than CALM-AF10 or negative cases. cTCR was found in 50%, compared to only 6% of HOX11L2 negative cases (p=0.01). All HOX11L2+ TCR + T-ALLs had undergone complete TCR V(D)J The immunophenotypic features of IM CALM-AF10 T-ALLs have been fully described. 39 CALM-AF10 was found in 29% (7/24) of TCR T-ALLs. It was not seen in HOX11L2 expressing cases and was found in pT and RAG-1 negative and positive cases (Table 3 and to as "Molecular Genetic" (MG) positive. We demonstrate for the first time that the incidence of these genetic abnormalities differs with age, but that the stage of maturation arrest is determined by the genotype, independent of age.
Quantitative analysis of LYL1, LMO2, TAL1 and LMO1 transcripts
Expression levels for each T-ALL, classified by genotype and immunophenotype and sorted for age are shown in Figure 4 . Overall, LYL1, LMO2, TAL1 and LMO1 were expressed by 35%, 31%, 30% and 8% of T-ALLs respectively (Table 4) .
Deregulation of TAL1, as defined by increased expression and/or SIL-TAL1 rearrangement, was more frequent within -lineage T-ALLs (42%; 41/98) than all other categories (13%, 10/75, p=0,00005). Within the -lineage, the mechanism of TAL1 deregulation was strikingly different in children and adults: it was due to SIL-TAL1 in 8/10 TAL1 deregulated pediatric cases, compared to only 9/31 adolescents and adults (p=0.004), when "idiopathic" TAL1 expression predominated. It is noteworthy that IM T-ALLs, particularly IM0, which might represent expansions of cells close to multipotential/myeloid precursors were TAL1 negative, as were the majority of HOX11 and HOX11L2 T-ALLs. Using the criteria defined here, only 85% of SIL-TAL1+ T-ALLs were TAL1+ (Fig. 4) . The 3 TAL1-cases demonstrated the lowest levels of SIL-TAL1 transcripts by RQ-PCR (data not shown) and were all LMO2 positive, compared to only 2/17 TAL1+ SIL-TAL1 + cases (p=0,01). LMO1 expression was found in two SIL-TAL1+cases.
LMO2 expression was most common in IM T-ALLs (Table 4) , demonstrating an abrupt diminution at the IM to TCR transition in CALM-AF10 T-ALLs and at the IM to IM transition in MG negative cases (Fig. 4) . LMO1 expression was less frequent and predominated within -lineage cases. Amongst SIL-TAL1+ and MG--lineage T-ALLs, 
DISCUSSION
We have recently shown that T-ALLs acurately reproduce thymic maturation and can be separated into expansions of the TCR and lineages, with the CALM-AF10 fusion transcript being specific for the latter. 38, 39 In the present study we demonstrate that TAL1
and HOX11 are specific to the -lineage whereas HOX11L2 identifies an intermediate / population. The stage of maturation arrest of each of these abnormalities is determined by genotype and is independent of age, whereas their incidence and their mechanism of deregulation varies with age, probably reflecting evolution in the population at risk and/or variable latency.
The vast majority of neonatal murine thymocytes belong to the -lineage, reflecting the massive cellular expansion induced by -selection following pre-TCR engagement. This process diminishes with age, probably secondary to the effect of IL7. 48 Since the incidence of DN thymocytes does not diminish, their proportion increases with age. 3, 6 This process is may also be operational in human thymic atrophy, since we show that leukemic transformation in pediatric T-ALL predominantly results in a mature, TCR+ stage of maturation arrest compared to a much more immature arrest in adult T-ALL, prior to completion of TCR rearrangement, which roughly corresponds to a DN1/DN2 murine thymocyte stage. 48, 49 The proportion of pre-TCR expressing, pre-T-ALLs, did not vary with age, although their genetic subtypes evolved markedly.
Ferrando et al. recently used gene expression profiles in pediatric T-ALL to demonstrate a closely related early cortical thymocyte stage of maturation arrest in HOX11 and HOX11L2
cases, earlier to the late cortical stage found in SIL-TAL1 cases. 22 We have used complementary immunophenotypic and TCR genotypic analyses to confirm and extend these data. HOX11 deregulation leads to a uniform, cortical thymocyte stage of maturation arrest (RAG-1+, pT +, cTCR +/V(D)J rearranged, sCD3-, CD1a+, CD4/8DP, TdT+, CD34-), in keeping with a population undergoing, or just about to undergo, -selection. Maturation of murine DN precursors to the DP stage requires expression of a pre-TCR.
Since normal TCR lymphocytes are not thought to express a pre-TCR or to undergo selection, expression of pT is not necessary for their development. 50 In the absence of either pT or TCR , some, albeit inefficient, maturation to the DP stage is possible by replacement of the pre-TCR by TCR . 51 Gounari et al. interpreted expression of a pTdriven reporter in TCR thymocytes as evidence of early TCR cells which have recently derived from a pT + common / precursor. 52 It is possible that the pT + TCR HOX11L2 T-ALLs described here correspond to these cells. The frequency of this category suggests either that common / precursors are particularly susceptible to leukemic transformation by HOX11L2 or, more likely, that HOX11L2 expression leads to a specific maturation arrest at this stage. Only half of the pT + TCR T-ALLs expressed HOX11L2, demonstrating that HOX11L2 expression is not the only mechanism leading to co-expression of TCR and pT .
The mechanisms leading to HOX11L2 deregulation are still unclear. Almost all are due to a cryptic translocation involving chromosome 5q35 and the CTIP2/BCL11B locus at chr.14q32 29 , but two t(5;14)(q32;q11) involving HOX11L2 and TCR / have been described. 53 Loss of BCL11B expression by homologous recombination leads to a DN block in murine thymic development, prior to complete TCR rearrangement and pT expression 54 , with no evidence of leukemic transformation. Our data demonstrating universal TCR rearrangement and pT expression is in keeping with BCL11B involvement in T cell oncogenesis as a transcriptional activator of HOX11L2, rather than as a tumor suppressor gene.
bHLH and their partner LMO1/2 proteins showed distinct profiles, with TAL1 and LMO1 predominating in -lineage T-ALLs and LYL1 and LMO2 in immature T-ALLs, as described for pediatric cases 22 . TAL1 deregulation in -lineage T-ALLs (approximately 40% of cases) was predominantly due to recombinase mediated SIL-TAL1 deletions in children but to currently unknown mechanisms in adults, shown to be due to deregulation in cis in the Jurkat cell line. 55 They are unlikely to be due to alternative SIL-TAL1 breakpoints, since the RT-PCR system used allows detection of the vast majority of recognized Enforced TAL1/LMO1/2 expression prevents the DN to DP transition and pT expression by titration of HEB, although the DP thymocytes which develop in these mice express higher pT levels than controls. 44 Our data would suggest that it is this latter population which is at risk of leukemic transformation, since the majority of TAL1 expressing T-ALLs were DP/CD8SP and expressed pT . They suggest that TAL1 deregulated T-ALLs are arrested either during -selection or at the DP to CD4-SP transition. These are precisely the checkpoints at which the levels of functional E2A proteins decrease, due either to an increase of Id proteins or diminution of E2A/HEB. 59 Our data support an "Id-like" role for TAL1, with its capacity to titrate-out E2A/HEB being critical at these 2 checkpoints. Such a titration effect may not require an LMO protein, which would fit with the fact that we often found TAL1 expression in the absence of LMO1 and LMO2.
We have previously shown that IM / T-ALL include expansions of TCR precursors. 38, 39 Co-expression of LMO2 and LYL1 was reported to reflect immaturity in pediatric T-ALL 22 ;
our data are in keeping with maintenance of these transcripts in precursors, which by extrapolation suggests that precursors are closer to a population with multilineage potential. Both transcripts were downregulated with TCR expression, particularly in adults. IM0/ / T-ALLs were not seen before 10 years of age. Their phenotype, their low level RAG-1 expression and the absence of recombinase mediated oncogenic rearrangements are all suggestive of an extrathymic origin. The absence of TAL1 expression is against transformation of a bone marrow multilineage precursor. Extra-thymic -lineage maturation is well recognised, predominantly in the gut or the fetal liver 60,61 , although the relatively late age of onset of these T-ALLs argues against a foetal onset.
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We found LYL1 expression in 35% of cases, compared to 38% and 22% of pediatric T-ALL series 22, 30 . Since LYL1 expression is commonest in IM, CALM-AF10 and HOX11L2 TALLs, its incidence is very dependent on the age range studied. TAL1/LYL1 amino-acid homology is restricted to the bHLH domain 40 , so it is likely that the consequences of LYL1
and TAL1 expression in T-ALLs is different, particularly if their action is not merely to titrate out E2A/HEB. The distinctive profiles of expression shown here are in support of this. Our data are in keeping with oncogenic synergy for LYL1 and LMO2 in IM0/ / TALLs, although we cannot exclude that these signatures are merely evidence of physiological expression of these transcripts by cCD3+,CD7+ precursors arrested prior to, or at an early stage of, -lineage development. It is probable that these T-ALLs are similar to immature AML and undifferentiated leukemia and that their clinical behavior differs markedly from -lineage restricted T-ALLs, particularly regarding cortico-sensitivity.
We show that the predominant pediatric oncogenic pathways are SIL-TAL1 and HOX11L2, which are progressively replaced by idopathic TAL1 deregulation, CALM-AF10 and, lastly, HOX11. The diminution in the incidence of SIL-TAL1 and HOX11L2 with age is in keeping with progressive diminution in the thymic -lineage, but it does not explain the late onset of HOX11 T-ALL (Table 2) . HOX11 is, at least partly, deregulated by the TCR / or TCR locus 11, 12, 32, 62 , whose activity are also likely to diminish with age. An increasing number of "idiopathic" HOX11 expressing T-ALLs are recognized. 33, 36 We consider that the age difference is more likely to reflect different oncogenic potential, in keeping with their different prognoses. 22, 30, 34, 63 HOX11L2 expression may provide a sufficiently strong oncogenic signal for development of leukemias after a relatively short latency, whereas HOX11 may require a further event. Newborn HOX11-/-mice exhibit asplenia and HOX11
is essential for the survival of splenic precursors during organogenesis but not for the initiation of splenic development. 64 Its enforced expression immortalizes embryonic yolk sac erythroid precursors 65 , blocks maturation of the J2E erythroid cell line 66 and transforms immature bone marrow precursors into IL3 dependent myeloid lines. It induces lymphoid tumors at low frequency with long latency. 67, 68 Taken together, HOX11 appears to immortalize, rather than transform, a variety of hematopoietic lineages. The second event could either correspond to the proliferative signal of -selection, but this is common to HOX11 and HOX11L2 expressing T-ALL, or to an additional oncogenic abnormality.
Thymocytes undergoing -selection demonstrate considerable apoptosis. It is possible that
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In conclusion, we demonstrate that 50% of T-ALLs demonstrate HOX11, HOX11L2, SIL-TAL1 or CALM-AF10 deregulation, with each being associated with a specific stage of maturation arrest: HOX11, SIL-TAL1 and HOX11L2 and represent -lineage oncogenes, despite TCR expression in the latter, and CALM-AF10 a -lineage oncogene (Fig. 3) .
The frequency of each genetic subgroup varies with age, suggesting variable latency and/or that thymic atrophy impacts on the population at risk of leukemic transformation and the mechanisms involved. Tables   Table 1 : RQ-PCR primer and probe sequences. HOX11L2 primers and probes are as described 30 . SIL-TAL1 detection was performed by RT-PCR as described 56 pT and RAG1 transcripts were evaluated relative to the levels observed in the HPB-ALL cell line. In order to compare levels of expression between transcripts, copy numbers were adjusted to 1.E-04
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